Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Chief Technology Officer | June 08, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.84 · Expires 2033-06-08 | Direct | 58,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 58,000 · Balance 58,000 F1: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2023 Filed Jun 12, 2023 20:57 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 58,000 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001104659-23-070410 · tm2318426-9_4seq1.xml · derivative · entry 1 ROBINSON MATTHEW K · CIK 0001934462 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: One-forty-eighth (1/48th) of the shares subject to such options shall vest monthly over forty-eight months after the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:06 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001104659-22-073102 · tm2218674-8_4seq1.xml · derivative · entry 1 ROBINSON MATTHEW K · CIK 0001934462 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on June 16, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.